Add to watchlist
€3.98
Last updated:06/10/2021
136: F
Adamas Pharmaceuticals, Inc

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkin… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-89.49M
-130.999M
-46.38%
-105.186M
+19.70%
-57.403M
+45.43%
Cashflow
Sum up money going in and out company
-66.827M
-104.223M
-55.96%
-80.779M
+22.49%
-50.708M
+37.23%
Total liabilities
All combined debts and obligations
120.05M
144.929M
+20.72%
163.051M
+12.50%
170.005M
+4.26%
Company profile
CEO
Mr. Neil F. McFarlane
Market capitalization
Micro (180.76M)